A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)

NCT00924781 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia
Chronic Kidney Disease

Interventions

DRUG: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline
DRUG: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline
DRUG: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline

Sponsor

Merck Sharp & Dohme LLC